
    
      This is a phase II, multi-center, randomized, double-blind, placebo-controlled, two arms
      study with 60 patients designed to evaluate the efficacy of Leronlimab (PRO 140) SC in
      patients with Nonalcoholic Steatohepatitis (NASH) for 13 weeks. Leronlimab (PRO 140 700 mg
      dose) or placebo will be weekly administered subcutaneously by a licensed healthcare
      professional at the clinic sites.

      A Follow Up visit will be conducted 28 (Â± 3) days after receiving the last study treatment
      (i.e., after last dose of Leronlimab (PRO 140) or placebo).
    
  